RE:Valuations based on bladder but....Hi valleyeast I added a highlight to your post that gives a better understanding of the point in time where the company plans to introduce the 2nd cancer indication trial being when a "majority" so implies greater then 2/3rds open & "recruiting" patients which again means not even treated. This really shows the level of confidence in their treatment .... thanks valleyeast ... good post.
valleyeast wrote
Arkady Mandel MD, Ph.D., D.Sc., Chief Scientific Officer at Theralase, stated: "It is exciting to witness Theralase's scientific and clinical research being widely recognized by prominent scientific and clinical organizations, internationally. These publications support the robustness of Theralase's technology and the clear advantages of using TLD-1433 in the treatment of NMIBC, indicating tremendous clinical and financial upside in Theralase's Ruthenium-based PDCs for treating other cancers. The success of Theralase's Phase Ib clinical study is a concrete example that PDT may soon play a significant role in the way oncology treatments are delivered in the future."
And
When Study II is well underway; with the majority of study sites open and recruiting patients, the Company expects to expand the breadth of indications by investigating an additional cancer indication in a Phase Ib human clinical study.
So if phase 2 is successful you might want to shift the decimal on the Mackie report.